U.S. Markets closed
  • S&P Futures

    3,639.75
    +3.25 (+0.09%)
     
  • Dow Futures

    29,869.00
    -5.00 (-0.02%)
     
  • Nasdaq Futures

    12,302.00
    +44.50 (+0.36%)
     
  • Russell 2000 Futures

    1,852.00
    -1.00 (-0.05%)
     
  • Crude Oil

    45.12
    -0.41 (-0.90%)
     
  • Gold

    1,789.10
    +1.00 (+0.06%)
     
  • Silver

    22.73
    +0.09 (+0.38%)
     
  • EUR/USD

    1.1972
    +0.0001 (+0.0120%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3330
    +0.0016 (+0.1213%)
     
  • USD/JPY

    104.0290
    -0.0560 (-0.0538%)
     
  • BTC-USD

    18,223.36
    +4.65 (+0.03%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    0.00 (0.00%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GLNG, ACB and ZSAN

·3 min read

NEW YORK, NY / ACCESSWIRE / November 13, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Golar LNG Limited (NASDAQ:GLNG)
Class Period: April 30, 2020 - September 24, 2020
Lead Plaintiff Deadline: November 23, 2020

According to the complaint, Golar LNG Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited (“Hygo”), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in GLNG: http://www.kleinstocklaw.com/pslra-1/golar-lng-limited-loss-submission-form?id=10942&from=1

Aurora Cannabis Inc. (NYSE:ACB)
Class Period: February 13, 2020 - September 4, 2020
Lead Plaintiff Deadline: December 1, 2020

The ACB lawsuit alleges that throughout the class period, Aurora Cannabis Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (ii) the Company's purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (iii) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ACB: http://www.kleinstocklaw.com/pslra-1/aurora-cannabis-inc-loss-submission-form-2?id=10942&from=1

Zosano Pharma Corporation (NASDAQ:ZSAN)
Class Period: February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline: December 28, 2020

Throughout the class period, Zosano Pharma Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ZSAN: http://www.kleinstocklaw.com/pslra-1/zosano-pharma-corporation-loss-submission-form?id=10942&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/616658/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-GLNG-ACB-and-ZSAN